Drug intelligence / Profile preview

ITL-1634

Development stage: Discontinued
Lead developer: ITL Pharma
Modality: Small Molecules

Overview

ITL-1634 (Parkinol) is a small molecule dopamine receptor agonist that was developed by ITL Pharmaceuticals for the treatment of Parkinson's disease. The compound was designed to target dopamine D2 and D3 receptors to provide symptomatic relief of motor symptoms such as tremors, rigidity, and bradykinesia. By mimicking the action of dopamine in the brain, ITL-1634 aimed to offer a more stable therapeutic effect and potentially reduce the off periods and dyskinesia associated with long-term levodopa use. The drug reached the IND-enabling stage of development in 2011, but no further clinical progress has been reported, and the program is considered inactive.

Brand names: Parkinol
Other names: Parkinol

Targets

DRD3 (Dopamine receptor D3)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on ITL-1634.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ITL-1634.

Explore the full profile